This study aims to explore the expression level of DNp63 in esophageal squamous cell carcinoma (ESCC). To investigate the association between DNp63 (p40) expression and ESCC biology, we compared the levels of DNp63 expression in normal and tumor tissues, with a specific focus on the diagnostic value of DNp63 in ESCC. We analyzed 160 consecutive patients with ESCC who underwent surgical resection without neoadjuvant chemotherapy at Gunma University Hospital (Maebashi, Japan) between September 2000 and January 2010. The clinicopathological characteristics and survival of patients were subclassified based on the expression of DNp63 as determined by immunohistochemistry, indicating that DNp63 was highly expressed in 75.6% (121/160) of ESCC patients. Clinicopathological analysis of DNp63 expression showed that DNp63-positive tumors significantly correlated with two important clinical parameters: T factor (P = 0.0316) and venous invasion (P = 0.0195). The 5-year overall survival rates of advanced ESCC patients with positive and negative expression of DNp63 were 35.6% and 71.7%, respectively. Multivariate analysis revealed that the expression of DNp63 was identified as an independent prognostic factor (P = 0.0049) in advanced ESCC. In line with this, DNp63a-transduced ESCC cell lines increased tumor growth in a soft agar colony formation assay. We report here for the first time that DNp63 expression increases the oncogenic potential of ESCC and is an independent marker for predicting poor outcome in advanced ESCC. Our findings suggest that DNp63 could serve as a new diagnostic marker for ESCC and might be a relevant therapeutic target for the treatment of patients with this disease. D espite recent advances in the treatment of esophageal squamous cell carcinoma (ESCC), the fight against ESCC is greatly confounded by the lack of an effective early detection strategy. Esophageal squamous cell carcinoma is considered to be an aggressive carcinoma based on its malignant transformation, carcinogenesis, invasion, and lymph node metastasis. (1, 2) A member of the p53 transcription factor family, p63 (TP63), shares significant homology with p53 and plays a role in maintaining the viability and proliferative capacity of basal epithelial cells.
D
espite recent advances in the treatment of esophageal squamous cell carcinoma (ESCC), the fight against ESCC is greatly confounded by the lack of an effective early detection strategy. Esophageal squamous cell carcinoma is considered to be an aggressive carcinoma based on its malignant transformation, carcinogenesis, invasion, and lymph node metastasis. (1, 2) A member of the p53 transcription factor family, p63 (TP63), shares significant homology with p53 and plays a role in maintaining the viability and proliferative capacity of basal epithelial cells. (3) Alternative splicing of the TP63 gene produces transcripts encoding two isoforms, one with (TAp63) and one without (DNp63) the transactivation domain. (4) (5) (6) The 3q27-q29 chromosomal region containing the TP63 gene is frequently amplified early in the development of squamous carcinoma (7, 8) and may play important roles in a variety of squamous cell carcinomas (SCCs) including lung, head and neck, bladder, and cervical cancers. (9) (10) (11) Indeed, the elevated expression of the DN isoform of p63 serves as a diagnostic marker used to distinguish SCC from adenocarcinoma in lung cancer, as well as CK5/6 or CK14. (8, (12) (13) (14) (15) DNp63 serves as a transactivator through a second transactivation domain and also acts as a dominant-negative transcriptional repressor that inhibits p53-or TAp63-mediated transcription, activities that are consistent with its potential role as an oncogene. (5, 16, 17) Although these findings suggest that DNp63 is an SCC oncogene, the biological roles and the pathologic relevance of p63 in tumorigenesis have not been fully elucidated. (18, 19) Additionally, the loss of p53 function is considered to play an essential role in carcinogenesis and the progression of esophageal cancer malignancies. (20, 21) The TAp63 isoforms are inhibited by interactions with cancer-associated p53 mutants. (11, 22) In this report, we investigate the association between the expression of DNp63 and ESCC biology. We assess the expression of DNp63 in ESCC tumors using immunohistochemistry and clinicopathological studies.
Materials and Methods
Cell lines and plasmids. The human ESCC cell lines, TE-1 and TE-8, were obtained from RIKEN BRC (Tsukuba, Japan) and previously described. (23) TE-1 and TE-8 cells were cultured in RPMI-1640 with 10% FBS at 37°C in a 5% CO 2 incubator. Human cDNA encoding FLAG-tagged DNp63a was subcloned into the LPCX retroviral expression vector (Takara Bio, Shiga, Japan). The sequence of the above construct was verified using DNA sequencing.
Patients. This study included 160 consecutive patients with ESCC who underwent surgical resection at Gunma University Hospital (Maebashi, Japan) between September 2000 and January 2010. All patients underwent R0 resection without preoperative adjuvant therapy. No patient was excluded from this investigation. The age of the patients ranged from 56 to 84 years (median age, 64 years). The study was approved by the institutional review board of Gunma University. The authors' approach to the evaluation and resection of these tumors has been described previously. (23) Formalin-fixed and paraffin-embedded primary tumor samples from the 160 patients were examined. All surgical specimens were reviewed and classified according to the WHO system by an experienced pathologist who was unaware of the clinical or imaging findings. Pathological TNM stages were established using the International System for Staging adopted by the AJCC and the UICC. All patients had tumors with SCC histology, of which 64 were stage T1 and 96 were stage T2-4. The day of surgery was the starting day for the measurement of postoperative survival. The follow-up duration ranged from 22 to 3983 days (median, 1470 days). In terms of postoperative treatment, 49.4% (79/160) of all ESCC patients received postoperative chemotherapy (mainly 5-fluorouracil-based chemotherapy), 43.8% (53/121) of positive DNp63 expressors and 66.7% (26/ 39) of negative DNp63 expressors (Table S1 ). None of 160 ESCC patients received radiotherapy as postoperative treatment. The study was carried out according to the Reporting Recommendations for Tumour Marker Prognostic Studies guidelines. (24) We used the term "prognostic marker" according to the guidelines.
Immunohistochemistry. Immunohistochemical analysis was carried out on formalin-fixed and paraffin-embedded ESCC sections. The sections were deparaffinized, blocked in Protein Block Serum-Free Reagent (Dako, Carpinteria, CA, USA) for 30 min, and incubated overnight with diluted primary antibodies at 4°C in a humidified chamber. Staining reactions were developed using Histofine Simple Stain MAX-PO Multi Kit (Nichirei, Tokyo, Japan) for immunohistochemistry. Meyer's hematoxylin (IHC World, Woodstock, MD, USA) was used as a nuclear counterstain.
Expression of DNp63 and p53 was determined by immunohistochemical staining with an anti-DNp63 rabbit polyclonal antibody (1:100 dilution) and an anti-p53 mouse mAb (DO7, 1:50 dilution; Dako) as previously described. (25, 26) DNp63 expression was considered positive if nuclear staining was present, and was scored semiquantitatively based on the percentage of positive cells as follows: 0, 0%; 1, 1%-25%; and 2, >25%. Tumors scored as 0 were defined as negative expression, and those scored as 1 or 2 were defined as positive expression. P53 microscopic examination for the nuclear reaction product was undertaken and scored. P53 expression in >10% of tumor cells was defined as positive expression. The tissue sections were assessed using light microscopy in a blinded fashion by at least two of the authors.
Statistical analysis. Fisher's exact test was used to examine the association of two categorical variables. The correlation between different variables was analyzed using the non-parametric Spearman's rank test. Follow-up for these 160 patients was undertaken using patient medical records. The KaplanMeier method was used to estimate survival as a function of time, and survival differences were analyzed using the logrank test. The day of surgery was defined as the starting day for the measurement of postoperative survival. Overall survival (OS) was determined as the time from tumor resection to the time of death from any cause. Disease-free survival was defined as the time between tumor resection and the first disease progression or death. Multivariate analyses were carried out using a stepwise Cox proportional hazards model to identify independent prognostic factors. Statistical analyses were undertaken using JMP (SAS Institute, Cary, NC, USA).
Quantitative real-time RT-PCR. The method for real-time RT-PCR was described previously. (26, 27) In short, total RNA was Anchorage-independent growth (soft agar colony formation assay). TE-1 and TE-8 cells were retrovirally transduced with DNp63. For soft agar assays, the cells were grown in triplicate for 10 days, after which anchorage-independent growth was quantified with a CytoSelect-96 kit (Cell Biolabs, San Diego, CA, USA).
Results
Immunohistochemical analyses. Clinicopathological data and surgically resected tumor specimens were collected from the 160 patients included in this study. The majority of patients were men (89.4%). All patients received radical surgery, having evidence of superficial ESCC (pathological stage T1, 40.0%) or advanced ESCC (pathological stage T2-4, 60.0%).
Squamous cell carcinomas frequently display evidence of simultaneous upregulation of both TAp63 and DNp63. DNp63 is a putative diagnostic marker for pulmonary SCC. (18) Representative examples of DNp63 protein expression in tumor tissue samples are shown in Figure 1 . DNp63 was observed in the cell nuclei of the basal and parabasal layers of non-cancerous specimens (Fig. S1a) ; elevated DNp63 expression was observed in 75.6% (121/160) of ESCC tumor tissues, predominantly localized in the nucleus. The aberrant expression of DNp63 was observed early in carcinogenesis; cases that maintained such expression in advanced cancer might have a poor prognosis. There is a factor related to the stability of DNp63 that may result in a poor prognosis in cases where DNp63 expression is maintained. A similar predominant expression of DNp63 is found in atypical nuclei of precancerous cases like intra-epithelial neoplasia, compared to normal esophagus, in which p63 staining is restricted to the proliferating basal and parabasal esophageal cell layers (Fig. S1b) . (28, 29) Clinicopathological factors. The clinicopathological factors and tumor expression of DNp63 of the 160 patients included in this study are shown in Table 1 . A clinicopathological analysis of DNp63 expression showed that DNp63-positive tumors significantly correlated with two important clinical parameters: T factor (P = 0.032) and venous invasion (P = 0.019). Tumors that were positive for DNp63 expression were more common in Table 1 . Demographics of 160 patients with esophageal squamous cell carcinoma (ESCC) according to DNp63 expression Remarkably, patient survival was significantly associated with DNp63 expression and N factor, as assessed by univariate analysis. Multivariate analysis confirmed that DNp63 expression and disease stage were independent prognostic factors in lung SCC patients with poor progression-free survival and OS (Table 2 ). Multivariate analysis confirmed that the expression of DNp63 was an independent prognostic factor for poor OS in advanced ESCC (P = 0.006) but not superficial ESCC (Table 2 ), whereas N factor had no significant correlation (Table 2) . Additionally, there were no statistically significant differences in age, sex, lymph node metastasis, or distant metastasis with respect to the level of DNp63 expression. Unlike in advanced ESCC cases, DNp63 was not prognostic factor in superficial ESCC cases (Table S2) .
Prognosis. The 5-year OS rate for all patients was 56.7%, and the 5-year OS rate and median survival time for advanced ESCC patients was 48.4% and 35.2 months, respectively. Table 2 shows the results of univariate and multivariate analyses of OS in advanced ESCC patients. The univariate analysis revealed that DNp63 expression and N factor had a significant relationship with OS. Figure 2 shows the Kaplan-Meier survival curve for ESCC patients as defined by the expression of DNp63 (Fig. 2) . The 5-year OS rates of advanced ESCC with high and low expression of DNp63 were 35.6% and 71.7%, respectively (P = 0.019). The prognosis of the DNp63-positive group was worse than that of the DNp63-negative group, although the difference was not statistically significant (P = 0.152).
In order to confirm the functional relevance of DNp63 expression during ESCC tumorigenicity, we monitored the colony formation of TE-1 and TE-8 ESCC cells transduced with DNp63 retrovirus. As shown in Figure 3(a,b) , DNp63 expression in either TE-1 or TE-8 cells led to increased anchorageindependent colony formation in soft agar, suggesting that the upregulation of DNp63a increases tumor formation.
Overall, our results indicate that DNp63 has oncogenic activity in ESCC both in clinicopathological relevance and in vitro, and further suggest that DNp63 could be a critical driver of tumor propagation in ESCC.
Discussion
In this study, we observed that the group of patients with advanced ESCC had a significantly lower frequency of DNp63-positive tumors than did the group with early stage cancer. In addition, we found that DNp63 expression in advanced ESCC tumors is associated with a poor prognosis.
The function of p63 is indispensable to normal epidermal stratification and the proliferative potential of epithelial stem cells, whereas the DN isoform of p63 is thought to maintain the proliferative potential of basal regenerative cells, including stem cells in the skin, thymus, breast, prostate, and urothelial stratified epithelium. (3, 10, (30) (31) (32) Our results suggest that DNp63 expression is of diagnostic value in ESCC and is an independent prognostic factor in advanced ESCC, although these results were not statistically significant for the total cases of ESCC.
The expression of DNp63 has been reported as a highly specific diagnostic marker of various human SCCs, including lung, head and neck, bladder, and cervical cancers. (8) (9) (10) (11) In fact, the amplification and overexpression of p63 has been frequently observed in lung cancers and in head and neck cancers. (11) The expression of DNp63 is reported to be significantly lower in invasive ESCC and to have a negative correlation with poor prognosis (33) whereas the expression of p63 decreases during the progression of lung, breast, and bladder cancer. Moreover, the loss of p63 expression is associated with poor prognosis in some cases. (31, 34, 35) In this study, our results suggested that the remaining DNp63-expression cases in advanced ESCC are correlated with poor prognosis, and that DNp63 is involved in the early development of SCC. (7, 8) The exact mechanism needs to be clarified that DNp63-expression remains in advanced ESCC with poor prognosis. In superficial ESCC, DNp63 expression was not found to be a prognostic factor (Table S2) . Although functional evaluation of p63 was not fully studied and the bias of postoperative treatment could not be completely excluded, we concluded that DNp63 could play a role in carcinogenesis and tumor progression in ESCC. (26, 34) Our results showed that the proportion of positive DNp63 expression was high in patients without venous invasion compare to patients with venous invasion. However, T factor and DNp63 are significantly correlated (Table S3 , P < 0.0001), we evaluate that venous invasion was affected by T factor.
Although high expression of DNp63 correlates with poor prognosis in patients with a variety of tumors, this correlation is stronger in patients whose tumors also have a mutation in the p53 gene. (36) The correct balance between the tumor-suppressive role of the TA isotype and the oncogenic role of the DN isotype, along with the tissue-specific environment, may be essential for the proliferation and differentiation of both epithelial stem cells and cancer stem cells. Whereas we could not establish a significant correlation between DNp63 and mutant p53 (Fig. 1, Table 1 ), the interaction between mutant p53 and p63 is reported to regulate the expression of p63 target genes to enhance invasion and metastasis. (37) Hence, the oncogenic activity of DNp63 might be a consequence of the physical association between DNp63 and mutant p53. (25, 38) Recent evidence indicates that inhibition of the p53/NF-Y complex by mutant gain of p53 function enhances expression of platelet-derived growth factor receptor-b and promotes metastasis in a subset of pancreatic cancers. (39) Syntaxin binding protein 4 is reported to physically interact with DNp63 and to play a crucial role in driving lung SCC growth through platelet-derived growth factor receptor-a signaling in a DNp63-dependent manner, which is consistent with a putative diagnostic role for DNp63. (26) The results of this study differ with respect to prognostic factor findings from those of other studies. Although previous reports described a poor prognosis for DNp63-negative cases, similar to our study, lower expression was more frequently observed in cases with worse tumor invasion. Our clinical samples are newer than those of previous reports, and there might be a smaller number of cases with early stage ESCC that are treatable by endoscopic submucosal dissection. The limitation of this study is that it is retrospective in nature and was undertaken at a single center with a small number of cases. Despite the retrospective analysis, none of the cases involved neoadjuvant chemotherapy, and the clinical conditions did not differ.
We report here for the first time that DNp63 expression increases the oncogenic potential of ESCC and serves as an independent prognostic marker for predicting poor outcome in advanced ESCC. Our findings suggest that DNp63 is a new diagnostic marker for ESCC and might be a relevant therapeutic target for the treatment of patients with this disease.
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